Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

1 May 2014 07:00

RNS Number : 0079G
Instem plc
01 May 2014
 



 

 

Instem plc

("Instem" or the "Company")

 

Contract Win

 

Instem's Provantis and Centrus solutions selected by WIL Research to replace and enhance its toxicology systems and processes worldwide

 

Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces today that it has been selected by WIL Research ("WIL") as its exclusive non-clinical technology partner, to optimise study-related processes at all WIL worldwide sites.

 

Key Facts

· Instem technology to replace all existing study management systems at WIL Research

· WIL Research selects all Provantis Preclinical Study Management modules

· Using Instem's Centrus-submit solution, WIL Research will become SEND (Standard for Exchange of Nonclinical Data) enabled

· WIL Research to leverage Instem's market leading SaaS model for worldwide deployment

 

WIL Research has approximately 1,200 staff offering a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.

 

WIL Research has chosen Instem's entire Provantis software suite, including its Logbook ELN solution for paper form replacement, as part of a multi-year project. Instem's Toxicology Resource Planning ("TRP") solution is also a key element of the Provantis deployment, increasing efficiencies by enabling WIL Research to plan and manage studies and programs, allocate resources, benchmark against past studies and plan workloads for the future.

WIL Research has additionally selected Instem's Centrus-submit™ solution to support SEND, the standardised reporting format for nonclinical data. The submit solution suite converts data from any source system into SEND files and allows sponsors, CROs and regulators such as the FDA to share, visualise and analyse study data more efficiently.

 

David Spaight, Chief Executive Officer at WIL Research, commented: "We are delighted to announce our enhanced partnership with Instem on a global level to deploy a comprehensive solution for toxicology data collection and management across our facilities situated in the United States, the Netherlands and in France. By leveraging our existing experience with Provantis in France, this expanded platform will support growing demand from our clients requiring a common and seamless multi-site global study management solution."

 

Phil Reason, CEO of Instem plc, commented: "WIL's selection of Instem's technology to replace all of its existing study management systems is a significant endorsement of the quality of our solutions. WIL has been a valued customer of Instem for 7 years and we are excited that it has chosen to extend that relationship as part of the technology-driven transformation that it is embarking upon. Instem has already secured SaaS revenues in excess of $2 million per annum and this provides further evidence of the attractiveness of this solution to clients. Demand for our offering remains strong and the growing proportion of SaaS contracts is leading to increasing visibility going forward."

 

 

 

 

 

 

For further information, please contact:

 

Instem plc

www.instem.com

Phil Reason, CEO

Tel: +44 (0) 1785 825 600

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or instem@walbrookpr.com

Bob Huxford

Mob: +44 (0)7747 635 908

Helen Cresswell

Mob: +44 (0)7841 917 679

 

 

 

About WIL Research

WIL Research is an interdisciplinary non-clinical contract research organisation providing product safety and toxicological assessment research and services to the international pharmaceutical, biotechnology, chemical, agricultural, veterinary, food and consumer products industries.

 

Find out more about WIL Research at www.wilresearch.com

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledgethrough the extraction and harmonisation of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQKKDBCBKDPQN
Date   Source Headline
15th Nov 20191:10 pmRNSCompletion of the Acquisition of Leadscope
15th Nov 20197:00 amRNSEarnings Enhancing Acquisition of Leadscope
16th Oct 20197:00 amRNSInformatics Update: Progressive Equity Note
1st Oct 201910:20 amRNSHolding(s) in Company
27th Sep 201912:45 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSHalf-year Report
13th Sep 20197:00 amRNSNotice of Results
15th Jul 20197:00 amRNSHalf Year Trading Update
3rd Jun 20195:06 pmRNSDirector/PDMR Shareholding
31st May 20197:37 amRNSHolding(s) in Company
24th May 20195:03 pmRNSDirector/PDMR Shareholding
23rd May 201911:26 amRNSResult of AGM
2nd May 20194:47 pmRNSPosting of Annual Report & Notice of AGM
29th Apr 20197:00 amRNSExercise of Options and Total Voting Rights
26th Apr 201910:59 amRNSHolding(s) in Company
18th Apr 20192:06 pmRNSSecond Price Monitoring Extn
18th Apr 20192:00 pmRNSPrice Monitoring Extension
15th Apr 20196:03 pmRNSHolding(s) in Company
15th Apr 20195:00 pmRNSHolding(s) in Company
12th Apr 20193:46 pmRNSHolding(s) in Company
12th Apr 201911:58 amRNSHolding(s) in Company
12th Apr 201911:52 amRNSHolding(s) in Company
12th Apr 20197:36 amRNSHolding(s) in Company
11th Apr 20199:49 amRNSResult of Secondary Placing
11th Apr 20197:00 amRNSProposed Placing to Sell 1,660,000 Shares
8th Apr 20196:01 pmRNSHolding(s) in Company
4th Apr 20191:48 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSNotice of Results
1st Mar 20195:50 pmRNSHolding(s) in Company
1st Mar 20197:00 amRNSHolding(s) in Company
28th Feb 201910:35 amRNSIssue of Equity and Total Voting Rights
20th Feb 20191:44 pmRNSExercise of Options, PDMR Dealing and TVR
19th Feb 20192:09 pmRNSDirector/PDMR Shareholding
22nd Jan 20197:00 amRNSTrading Update
7th Dec 20183:28 pmRNSHolding(s) in Company
2nd Oct 20187:00 amRNSExercise of Options and Total Voting Rights
24th Sep 20187:00 amRNSHalf-year Report
10th Sep 20187:00 amRNSNotice of Results
6th Aug 20181:39 pmRNSHolding(s) in Company
23rd Jul 20187:00 amRNSTrading Update
6th Jun 20187:00 amRNSContract win
24th May 201810:43 amRNSResult of AGM
16th May 20183:18 pmRNSNotice of AGM
26th Mar 20187:01 amRNSSEND Contract Extension and SEND Update
26th Mar 20187:00 amRNSFinal Results
16th Mar 20187:00 amRNSNotice of Results
12th Mar 20189:33 amRNSIssue of Equity and TVR
7th Mar 20187:00 amRNSSaaS Business Update
26th Feb 20187:00 amRNSGrants to Directors under the Instem LTIP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.